

**REMARKS/ARGUMENTS**

Claims 10-14 are pending.

In response to the restriction requirement, Applicant's elect to prosecute Group I claims directed to methods of inhibiting adhesion.

In a Preliminary Amendment dated November 12, 2003, submitted with the application, original claims 1-9 were canceled, and original claims 10-14 were retained. However, claim 11 was inadvertently replaced with language from claim 10 in the Preliminary Amendment. Therefore, claim 11 is canceled and replaced with new claim 15, which recites the language from original claim 11.

Claim 10 is amended to clarify that the method of inhibiting adhesion can involve both contortrostatin and biologically active contortrostatin variants. Support for this amendment is found at pages 15, line 3 – page 17, line 4. Accordingly, no new matter is added.

New claim 16 depends from claim 10 and is directed to contortrostatin. Support for this claim is found in original claim 10.

In view of the forgoing amendment, election and remarks, Applicants submit that the claims are in condition for allowance. A Notice of Allowance is therefore respectfully requested.

Dated: September 8, 2005

Respectfully submitted,



Miles Yamanaka  
Reg. No. 45,665

FULBRIGHT & JAWORSKI L.L.P  
555 South Flower Street , 41<sup>st</sup> Floor  
Los Angeles, CA 90071  
(213) 892-9200 – Telephone  
(213) 892-9494 - Facsimile